17-Hydroxyprogesterone blunts the hypertensive response associated with reductions in uterine perfusion pressure in pregnant rats

Am J Obstet Gynecol. 2009 Sep;201(3):324.e1-6. doi: 10.1016/j.ajog.2009.05.054.

Abstract

Objective: Reduction in uteroplacental perfusion (RUPP) in pregnant rats is associated with hypertension, elevated cytokines, and activation of the endothelin (ET-1) system. Our objective was to determine whether the antiinflammatory properties of 17-alpha-hydroxyprogesterone caproate (17 OHP) reduce cytokine-stimulated vasoactive pathways that are associated with hypertension in response to placental ischemia.

Study design: Mean arterial pressure (MAP), tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and renal ET-1 were measured in the following: pregnant controls, pregnant controls plus 17 OHP (6.6 mg/kg), RUPP rats, and RUPP rats plus 17 OHP.

Results: MAP increased 29 mm Hg in RUPP rats compared with pregnant controls (P < .001), whereas in RUPP plus 17 OHP rats, MAP increased only 19 mm Hg (P < .05). TNF-alpha and IL-6 increased 2- to 3-fold, respectively, in response to placental ischemia but was normalized in RUPP rats treated with 17 OHP. ET-1 increased 3-fold in RUPP rats but was markedly less in RUPP plus 17 OHP rats.

Conclusion: 17 OHP blunts hypertension associated with RUPP, possibly via suppression of cytokine-stimulated ET-1 activation.

MeSH terms

  • 17 alpha-Hydroxyprogesterone Caproate
  • 17-alpha-Hydroxyprogesterone / pharmacology*
  • Animals
  • Endothelin-1 / physiology
  • Female
  • Hydroxyprogesterones / pharmacology
  • Ischemia / drug therapy
  • Ischemia / physiopathology
  • Placenta / blood supply
  • Placental Circulation / drug effects*
  • Placental Circulation / physiology*
  • Pregnancy
  • Progesterone Congeners / pharmacology
  • Rats
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Endothelin-1
  • Hydroxyprogesterones
  • Progesterone Congeners
  • Tumor Necrosis Factor-alpha
  • 17 alpha-Hydroxyprogesterone Caproate
  • 17-alpha-Hydroxyprogesterone